Bio Essence Corporation Reports Revenue Surge to $500,537 and Net Income Turnaround

Bio Essence Corporation reported significant financial improvements in its latest quarterly results, with revenues for the three months ending March 31, 2026, reaching $500,537, a substantial increase from $22,189 in the same period last year. This growth was primarily driven by a surge in Original Equipment Manufacturer (OEM) service orders, including large contracts from a new major customer. The company's gross profit also saw a notable rise, climbing to $319,353 compared to $20,588 in the previous year, reflecting a gross margin of 63.8% for the current quarter.

In terms of operational efficiency, Bio Essence reduced its operating expenses significantly, reporting $103,558 for the latest quarter, down from $225,680 a year earlier. This decrease was largely attributed to lower general and administrative costs, which fell by 54.3% to $102,878, as the company streamlined its operations following the divestiture of its subsidiaries. The net income for the quarter was $205,373, a remarkable turnaround from a net loss of $205,752 in the prior year, marking an increase of $411,125 or 199.82%.

The company’s balance sheet reflects a total asset value of $789,032 as of March 31, 2026, compared to $422,474 at the end of 2025. Current assets increased significantly, driven by a rise in accounts receivable and advances to vendors, which totaled $788,994, up from $422,377. However, total liabilities also rose to $2,216,552, leading to a stockholders' deficit of $1,427,520, an improvement from $2,072,893 at the end of the previous fiscal year.

Bio Essence has been actively restructuring its operations, having sold its manufacturing and distribution subsidiaries in late 2023, which has allowed it to focus on its core OEM services. The company is also exploring additional business opportunities and potential acquisitions to further enhance its market position. As of March 31, 2026, the company had 46,809,000 shares of common stock outstanding, an increase from 38,009,000 shares at the end of 2025, following a private placement that raised $440,000 for general corporate purposes.

Looking ahead, Bio Essence acknowledges the challenges posed by its accumulated deficit of $9,347,700 and the need for additional financing to support its operations. Management is optimistic about its strategy to increase revenue through enhanced sales efforts and marketing initiatives, while also considering various funding options, including public or private offerings. However, the company cautions that its ability to continue as a going concern is contingent upon successfully implementing its business plan and securing necessary funding.